-+ 0.00%
-+ 0.00%
-+ 0.00%
Actuate Therapeutics Announces Preclinical Data Demonstrating That Daily Oral Administration Of Elraglusib Achieved Up To 77% Tumor Growth Inhibition As Monotherapy In An Aggressive Melanoma Model
Share
Listen to the news

Daily oral elraglusib achieved up to 77% tumor growth inhibition as monotherapy in an aggressive preclinical melanoma model, with greater antitumor activity observed at higher drug exposures
Treatment was associated with changes in the tumor immune microenvironment, characterized by increased cytotoxic T cells and natural killer cells and reduced immunosuppressive myeloid cells
Findings further reinforce initiation of Phase 1/2 clinical trial in Q1 2027 with daily dosing of elraglusib oral tablet

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending